The goal of this project is to characterize the structure, function, and regulation of the reduced folate carrier (RFC), the major membrane transport system for reduced folate cofactors in mammalian cells. An adequate supply of folates is essential for growth and development of all tissues and there is increasing evidence that folate deficiency contributes to chromosomal instability and malignant transformation. RFC transport is also critical to antitumor activities of methotrexate and a new generation of antifolates typified by Tomudex and Pemetrexed, and RFC alterations result in decreased drug uptake and contribute to antifolate resistance. This renewal application expands on recent significant advances by our laboratory including: (a) characterization of the human RFC (hRFC) gene and demonstration of a remarkable complexity of transcriptional and posttranscriptional controls involving 6 alternately spliced 5'non-coding exons (A1/2,A,B,C,D,E) and unique promoters mapping over 35 kb upstream from the translational start; (b) identification of functionally or structurally important charged amino acids (D88,R133,R373,K411) or domains [transmembrane domain (TMD) 6/7 linker; residues 204-214]; (c) development of a functional """"""""cysteine-less"""""""" hRFC and localization of transport function to an exofacial loop domain flanking TMD 1 by substituted cysteine accessibility methods (SCAM) with thiol reactive agents; (d) partial determination of hRFC membrane topology (TMDsl-8); and (e) purification of epitope (His10)-tagged hRFC. For our continued studies, we will in Aim 1 (i) establish the topology of TMDs 9-12 and TMD-loop boundaries, and (ii) map putative binding sites for (anti)folate substrates by SCAM, expression of mouse-human chimera RFCs, radioaffmity labeling of His10-tagged hRFC protein, and site-directed mutagenesis. (iii) hRFC oligomeric structures will be characterized by co-fractionation of HA-/His10-tagged hRFCs, analytical gel filtration, and proteoliposome reconstitution.
In Aim 2, we will establish (iv) the patterns of 5'UTR and promoter utilization in human tissues, tumors, and cell lines by real-time PCR and RNAse protection. Other studies will characterize: (v) the major regulatory features (e.g., cis elements, transcription factors) of the hRFC-A1/2, -D, and -E promoters; (vi) posttranscriptional controls including effects of the major 5' untranslated regions (UTRs) and splice forms on translational efficiencies and transcript stabilities, and on hRFC levels and function; and (vii) the significance of novel hRFC isoforms translated from in-frame AUGs in the A1/2 and A 5'UTRs. Based on these results, we will (viii) characterize the transcriptional and posttranscriptional regulation of hRFC by cellular folates and/or by pharmacologic manipulations that alter folate/nucleotide pools. Our studies should identify on the major regulatory properties of the hRFC gene and heterogeneous hRFC transcripts in human tumors and tissues, and the molecular determinants of folate and antifolate substrate binding and membrane translocation by the hRFC protein.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA053535-17
Application #
7383084
Study Section
Special Emphasis Panel (ZRG1-CII (02))
Program Officer
Forry, Suzanne L
Project Start
1993-02-12
Project End
2009-04-30
Budget Start
2008-04-01
Budget End
2009-04-30
Support Year
17
Fiscal Year
2008
Total Cost
$255,033
Indirect Cost
Name
Wayne State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Shah, Khushbu; Raghavan, Sudhir; Hou, Zhanjun et al. (2018) Development and validation of chemical features-based proton-coupled folate transporter/activity and reduced folate carrier/activity models (pharmacophores). J Mol Graph Model 81:125-133
Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
Giovannetti, E; Zucali, P A; Assaraf, Y G et al. (2017) Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. Ann Oncol 28:2725-2732
Hou, Zhanjun; Gattoc, Leda; O'Connor, Carrie et al. (2017) Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor ? and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates. Mol Cancer Ther 16:819-830
Wilson, Mike R; Hou, Zhanjun; Yang, Si et al. (2016) Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates. Mol Pharmacol 89:425-34
Golani, Lalit K; Wallace-Povirk, Adrianne; Deis, Siobhan M et al. (2016) Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesi J Med Chem 59:7856-76
Wilson, Mike R; Hou, Zhanjun; Wilson, Lucas J et al. (2016) Functional and mechanistic roles of the human proton-coupled folate transporter transmembrane domain 6-7 linker. Biochem J 473:3545-3562
Wang, Yiqiang; Mitchell-Ryan, Shermaine; Raghavan, Sudhir et al. (2015) Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents. J Med Chem 58:1479-93
Wang, Lei; Wallace, Adrianne; Raghavan, Sudhir et al. (2015) 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor ? and the Proton-Coupled Folate Transporter in Human Tumors. J Med Chem 58:6938-59

Showing the most recent 10 out of 32 publications